Literature DB >> 20082185

High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Hendrik Andreas Wolff1, Jochen Gaedcke2, Klaus Jung3, Robert Michael Hermann1,4, Hilka Rothe5, Markus Schirmer6, Torsten Liersch2, Markus Karl Alfred Herrmann1, Steffen Hennies1, Margret Rave-Fränk1, Clemens Friedrich Hess1, Hans Christiansen7,8.   

Abstract

PURPOSE: To test for a possible correlation between high-grade acute organ toxicity during preoperative radiochemotherapy and complete tumor regression after total mesorectal excision in multimodal treatment of locally advanced rectal cancer. PATIENTS AND METHODS: From 2001 to 2008, 120 patients were treated. Preoperative treatment consisted of normofractionated radiotherapy at a total dose of 50.4 Gy, and either two cycles of 5-fluorouracil (5-FU) or two cycles of 5-FU and oxaliplatin. Toxicity during treatment was monitored weekly, and any toxicity CTC (Common Toxicity Criteria) >or= grade 2 of enteritis, proctitis or cystitis was assessed as high-grade organ toxicity for later analysis. Complete histopathologic tumor regression (TRG4) was defined as the absence of any viable tumor cells.
RESULTS: A significant coherency between high-grade acute organ toxicity and complete histopathologic tumor regression was found, which was independent of other factors like the preoperative chemotherapy schedule. The probability of patients with acute organ toxicity >or= grade 2 to achieve TRG4 after neoadjuvant treatment was more than three times higher than for patients without toxicity (odds ratio: 3.29, 95% confidence interval: [1.01, 10.96]).
CONCLUSION: Acute organ toxicity during preoperative radiochemotherapy in rectal cancer could be an early predictor of treatment response in terms of complete tumor regression. Its possible impact on local control and survival is under further prospective evaluation by the authors' working group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20082185     DOI: 10.1007/s00066-009-2037-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  28 in total

Review 1.  Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?

Authors:  R Glynne-Jones; M Wallace; J I L Livingstone; J Meyrick-Thomas
Journal:  Dis Colon Rectum       Date:  2007-11-28       Impact factor: 4.585

2.  Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy.

Authors:  Kerstin Borgmann; Ulrike Hoeller; Sven Nowack; Michael Bernhard; Barbara Röper; Sophie Brackrock; Cordula Petersen; Silke Szymczak; Andreas Ziegler; Petra Feyer; Winfried Alberti; Ekkehard Dikomey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

3.  [Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas].

Authors:  A Dietz; V Rudat; C Conradt; B Vanselow; P Wollensack; S Staar; H Eckel; P Volling; M Schröder; M Wannenmacher; R P Müller; H Weidauer
Journal:  HNO       Date:  2000-09       Impact factor: 1.284

4.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

5.  The impact of the haemoglobin level on the response to radiotherapy.

Authors:  A Haydaroğlu; V Yürüt; A Arican; D Yalman; A Bülent Aras; M Esassolak; S Ozkök
Journal:  J BUON       Date:  2002 Jan-Mar       Impact factor: 2.533

6.  The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck.

Authors:  Tiffany Daly; Michael G Poulsen; James W Denham; Lester J Peters; David S Lamb; Hedley Krawitz; Chris Hamilton; Jacqui Keller; Lee Tripcony; Quenten Walker
Journal:  Radiother Oncol       Date:  2003-08       Impact factor: 6.280

7.  Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C.

Authors:  Hans Christiansen; Robert M Hermann; Andrea Hille; Elisabeth Weiss; Mirko Nitsche; Alexios Martin; Clemens F Hess; Olivier Pradier
Journal:  Head Neck       Date:  2004-10       Impact factor: 3.147

8.  Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.

Authors:  Kathrin Dellas; Matthias Bache; Steffi U Pigorsch; Helge Taubert; Matthias Kappler; Daniel Holzapfel; Ester Zorn; Hans-Juergen Holzhausen; Gabriele Haensgen
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

9.  Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?

Authors:  Roy F A Vliegen; Regina G Beets-Tan; Bart Vanhauten; Ann Driessen; Michel Oellers; Alfons G Kessels; Ann Arens; Geerard L Beets; Jeroen Buijsen; Angela van Baardwijk; Dirk de Ruysscher; Guido Lammering
Journal:  Strahlenther Onkol       Date:  2008-09-19       Impact factor: 3.621

10.  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.

Authors:  D A Fein; W R Lee; A L Hanlon; J A Ridge; C J Langer; W J Curran; L R Coia
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  15 in total

1.  Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.

Authors:  Birgit Meller; Margarete Rave-Fränck; Christian Breunig; Markus Schirmer; Manfred Baehre; Roger Nadrowitz; Torsten Liersch; Johannes Meller
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

2.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

3.  Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results.

Authors:  K M Jang; S H Kim; D Choi; S J Lee; M J Park; K Min
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

4.  High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.

Authors:  Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

5.  A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Authors:  Deborah Citrin; Kevin Camphausen; Bradford J Wood; Martha Quezado; John Denobile; James F Pingpank; Richard E Royal; H Richard Alexander; Geoffrey Seidel; Seth M Steinberg; Yvonne Shuttack; Steven K Libutti
Journal:  Oncology       Date:  2011-03-25       Impact factor: 2.935

6.  Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.

Authors:  Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

7.  Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

Authors:  J Joshua Smith; Isaac Wasserman; Sarah A Milgrom; Oliver S Chow; Chin-Tung Chen; Sujata Patil; Karyn A Goodman; Julio Garcia-Aguilar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-18       Impact factor: 7.038

8.  Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.

Authors:  Hans Theodor Eich; Anna Stepien; Christian Zimmermann; Martin Hellmich; Ralf Metzger; Arnulf Hölscher; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-03-07       Impact factor: 3.621

9.  Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Authors:  M Niyazi; S B Schwarz; B Suchorska; C Belka
Journal:  Strahlenther Onkol       Date:  2012-01-11       Impact factor: 3.621

10.  Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005.

Authors:  O Guerin; J Gal; E Francois; B Jacqueme; V Sciortino; J P Gerard
Journal:  Strahlenther Onkol       Date:  2012-03-14       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.